For the quarter ending 2025-09-30, MBX made $26,377K in revenue. -$21,475K in net income. Net profit margin of -81.42%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 19,270 | 17,724 | ||
| General and administrative | 4,656 | 4,081 | ||
| Total operating expenses | 23,926 | 21,805 | ||
| Loss from operations | -23,926 | -21,805 | ||
| Interest and other income, net | 2,308 | 2,394 | ||
| Net loss | -21,618 | -19,411 | ||
| Unrealized gain on marketable securities | 143 | -42 | ||
| Total other comprehensive income | 143 | -42 | ||
| Total comprehensive loss | -21,475 | -19,453 | ||
| Earnings per share, basic, total | -0.63 | -0.58 | ||
| Earnings per share, diluted, total | -0.63 | -0.58 | ||
| Weighted average number of shares outstanding, basic, total | 34,198,597 | 33,446,385 | ||
| Weighted average number of shares outstanding, diluted, total | 34,198,597 | 33,446,385 | ||
MBX Biosciences, Inc. (MBX)
MBX Biosciences, Inc. (MBX)